
    
      The proposed study will evaluate a regimen using treosulfan, fludarabine and low-dose TBI in
      children and adolescents with AML or MDS undergoing allogeneic HCT. We expect this regimen to
      yield lower toxicity and at least equivalent rates of disease control and overall survival,
      compared to current standard myeloablative regimens. The primary objective of this study is
      to determine the safety and preliminary efficacy of a transplant preparative regimen
      consisting of treosulfan, fludarabine and low-dose TBI for children with AML and MDS. The
      primary endpoint will be overall survival (OS) at one year. Secondary objectives to be
      studied include: pharmacokinetic (PK) profile of treosulfan in children < 40 kg, non-relapse
      mortality, disease-free survival, incidences of neutrophil and platelet engraftment, donor
      chimerism, acute and chronic graft-versus-host disease (GVHD), and relapse.
    
  